The Therapeutic Effect of Avonex, Rebif and Betaferon on EDSS and Relapse in Multiple Sclerosis: A Comparative Study
,
Abstract
We aimed to compare the therapeutic effect of Avonex (Av), Betaferon (Be) & Rebif (Re) on the Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS). Ninety patients referring to Farshchian Hospital were entered in this study. The patients were divided into three equal groups: group 1 received Av, group 2 received Re and group 3 received Be, and after 24 months, comparison was done by calculating primary and final EDSS and the relapse rate. For comparison of the primary and final EDSS in each group, the relapse rate between the groups and side effects between the drugs, the paired samples t.test, the One-Way ANOVA test and the Pearson- chi-square were used. Average age was 31.11 ± 8.62 years, 80% being female. Comparison of the average primary and final EDSS using the paired samples t.test showed a significant statistical difference (P < 0.05). Motor and visual disturbances (respectively 68.3% and 60.3%) were the most common signs and relapsing- remitting form was the most common form (42.1%).The average EDSS change of groups Av, Be and Re was respectively, 1.28 (29.76%), 1.30(24.30%) and 1.26 (26.63%), showing no significant statistical difference in reducing EDSS. Groups Av and Be, showed no significant statistical difference in the average relapse rate before and after treatment, but in group Re there was a significant difference (P < 0.05). Treatment with these drugs reduces motor disability, with no significant difference between them. Also in comparison, Re has a greater effect in reducing the relapse rate, but again with no significant statistical difference among them.
Olek MJ, Dawson DM. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley GW, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice. 4th ed. Philadelphia: Butterworth & Heinemann; 2004. p. 1631-64.
Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs 2004;18(12):777-92.
Ropper AH, Brown RH. Multiple sclerosis and allied demyelinative disease. In: Victors M, Ropper AH, editors. Adam's and Victor's Principles of Neurology. 7th ed. New York: Mc Graw-Hill; 2005. p. 771-96.
Allen IV. Aetiological hypotheses for multiple sclerosis: evidence from human and experimental diseases. In: Matthews WB, editor. McAlpine's Multiple Sclerosis. 2nd ed. New York: Churchill Livingstone; 1991. p. 379-90.
Tornatore C, Bartlett D. Tolerability of interferon beta-1b (BetaferonTM/BetaseronTM) can be significantly improved using both interferon-free needle and automated injection techniques. J Neurol 2002;249(Suppl 1):205,814.
Samkoff LM. Multiple Sclerosis: update on treatment. Hosp Physician 2002;38(3):21-7.
The IFNB Multiple Sclerosis Study Group. Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43(4):655-61.
Jascobs LD, Cookfair DL, Rudick RA. Intramuscular interferon beta-1a for diseases progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
Rowland LP, editor. Merritt’s Neurology. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 958-60.
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113(5):283-7.
Milanese C, La Mantia L, Palumbo R. Interferon beta treatment in relapsing-remitting multiple sclerosis: a postmarketing study in Lombardia, Italy. Multiple Sclerosis Centers of Lombardia, Italy. Ital J Neurol Sci 1999;20(5):297-302.
Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122 ( Pt 4):625-39.
Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122( Pt 10):1941-50.
Milanese C, La Mantia L, Palumbo R. A post-marketing study on interferon beta 1b and 1a treatment in relapsingremitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74(12):1689-92.
Fernández O, Arbizu T, Izquierdo G, Martínez-Yélamos A, Gata JM, Luque G, et al. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study. Acta Neurol Scand 2003;107(1):7-11.
Kalanie H, Gharagozli K, Hemmatie A, Ghorbanie M, Kalanie AR. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran. Eur Neurol 2004;52(4):202-6.
Jensen D. Interferon therapy of multiple sclerosis. Tidsskr Nor Laegeforen 1999;119(21):3142-5.
The Multiple Sclerosis Information Trust. Diagnosing Multiple Sclerosis [Online]. Last Modified: 2008 Jun. Available from: URL: http://www.mult-sclerosis.org/diagnosingms.html
Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002;162(19):2161-9.
Wu X, Dastidar P, Kuusisto H, Ukkonen M, Huhtala H, Elovaara I. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS. Acta Neurol Scand 2005;112(4):242-7.
Zimmermann C, Walther EU, Goebels N, Lienert C, Kappos L, Hartung HP, et al. Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis. Nervenarzt 1999;70(8):759-63.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. ACP J Club 1999;130(3):68-9.
| Files | ||
| Issue | Vol 48, No 2 (2010) | |
| Section | Articles | |
| Keywords | ||
| Multiple sclerosis interferon beta 1a interferon beta 1b | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
